Intensive lipid-lowering therapy: obvious benefits, possible risks.
Zimlichman
Eyal
E
Department of Internal Medicine B, Sheba Medical Center, Tel Hashomer, Israel Affiliated to Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel. zimliche@post.tau.ac.il
Szyper-Kravitz
Martine
M
Katz
Uriel
U
Shoenfeld
Yehuda
Y
D000369:Aged, 80 and over; D001384:Azetidines / Q000008:administration & dosage / Q000009:adverse effects*; D003327:Coronary Disease / Q000209:etiology / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D000069438:Ezetimibe; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D006937:Hypercholesterolemia / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D009135:Muscular Diseases / Q000139:chemically induced*
D001384:Azetidines; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D000069438:Ezetimibe